The influence of alendronate on spine fusion in an osteoporotic animal model

Spine

Volumn 36, Issue 18, 2011, Pages 1446-1452

  Nakao, Shin Ichi ^a   Minamide, Akihito ^a   Kawakami, Mamoru ^a   Boden, Scott D ^b   Yoshida, Munehito ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

alendronate; bisphosphonate; lumbar; osteoporosis; rat; spine fusion

Indexed keywords

ALENDRONIC ACID; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE RADIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HISTOLOGY; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOPOROSIS; OVARIECTOMY; PRIORITY JOURNAL; RAT; SPINE FUSION;

ALENDRONATE; ANIMALS; BIOMECHANICS; BONE DENSITY CONSERVATION AGENTS; BONE TRANSPLANTATION; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; LUMBAR VERTEBRAE; OSTEOGENESIS; OSTEOPOROSIS; OVARIECTOMY; RATS; RATS, SPRAGUE-DAWLEY; SPINAL FUSION; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 80051788861     PISSN: 03622436     EISSN: 15281159     Source Type: Journal    
DOI: 10.1097/BRS.0b013e3181f49c47     Document Type: Article

References (28)

1. National Institute of Health. Osteoporosis prevention, diagnosis, and therapy. National Institutes of Health Consensus Statement, March 27-29, 2000; 17 ( 1 ): 1-45.
2. Qin L, Choy W, Au S, et al. Alendronate increases BMD at appendicular and axial skeletons in patients with established osteoporosis. J Orthop Surg 2007; 21-9.
3. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280 ( 24 ): 2077-82.
4. Sato M, Grasser W. Effects of bisphosphonates on isolated rat osteoclasts as examined by refl ected light microscopy. J Bone Miner Res 1990; 5: 31-40.
5. Sato M, Grasser W, Endo N, et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991; 88: 2095-105.
6. Fisher JE, Rogers MJ, Halasy JM, et al. Alendronate mechanism of action: geranylgeraniol, and intermediate in the mevalonate pathway, prevents inhibition of osteoclast function, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci U S A 1999; 96: 133-8.
7. Srisubut S, Teerakapong A, Vattraphodes T, et al. Effect of local delivery of alendronate on bone formation in bioactive glass grafting in rats. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 104: e11-6.
8. Xue Q, Li H, Zou X, et al. The infl uence of alendronate treatment and bone graft volume on posterior lateral spine fusion in a porcine model. Spine (Phila Pa 1976) 2005; 30: 1116-21.
9. Sama AA, Khan SN, Myers ER, et al. High-dose alendronate uncouples osteoclast and osteoblast function: a study in a rat spine pseudarthrosis model. Clin Orthop Relat Res 2004; 425: 135-42.
10. Lehman RA, Kuklo TR, Freedman BA, et al. The effect of alendronate sodium on spinal fusion: a rabbit model. Spine J 2004; 4: 36-43.
11. Huang RC, Khan SN, Sandhu HS, et al. Alendronate inhibits spine fusion in a rat model. Spine (Phila Pa 1976) 2005; 30: 2516-22.
12. Gerts BJ, Holland SD, Kline WF, et al. Clinical pharmacology of alendronate sodium. Osteoporosis Int 1993; 3 ( Suppl 3 ): S13-6.
13. Feiertag MA, Boden SD, Schimandle JH, et al. A rabbit model for nonunion of lumbar intertransverse process spine arthrodesis. Spine 1996; 21: 27-31.
14. Iwamoto J, Seki A, Takeda T, et al. Comparative effects of alendronate and alfacalcidol on cancellous and cortical bone mass and bone mechanical properties in ovariectomized rats. Exp Anim 2006; 55: 356-67.
15. Fuchs RK, Shea M, Durski SL, et al. Individual and combined effects of exercise and alendronate on bone mass and strength in ovariectomized rats. Bone 2007; 41: 290-6.
16. Omi N, Goseki M, Oida S, et al. The nutritional evaluation of globin on maintenance of bone metabolism in ovariectomized osteoporotic rats. J Nutr Sci Vitaminol (Tokyo) 1994; 40 ( 5 ): 443-57.
17. Peter CP, Cook WO, Nunamaker DM, et al. Effect of alendronate on fracture healing and bone remodeling in dogs. J Orthop Res 1996; 14: 74-9.
18. Kim KW, Ha KY, Moon MS, et al. Volumetric change of the graft bone after intertransverse fusion. Spine (Phila Pa 1976) 1999; 24: 428-33.
19. Altundal H, Gursoy B. The infl uence of alendronate on bone formation after autogenous free bone grafting in rats. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005; 99: 285-91.
20. Tenenbaum HC, Torontali M, Sukhu B. Effects of bisphosphonates and inorganic pyrophosphate on osteogenesis in vitro. Bone 1992; 13: 249-55.
21. Goziotis A, Sukhu B, Torontali M, et al. Effects of bisphosphonates APD and HEBP on bone metabolism in vitro. Bone 1995; 16: 317S-27S.
22. von Knoch F, Jaquiery C, Kowalsky M, et al. Effect of bisphosphonate on proliferation and osteoblast differentiation of human bone marrow storomal sells. Biomaterials 2005; 26: 6941-5.
23. Duque G, Rivas D. Alendronate has an anabolic effect on bone through the differentiation of mesenchymal stem cells. J Bone Miner Res 2007; 22: 1603-11.
24. Cottrell JM, van der Meulen MC, Lane JM, et al. Assessing the stiffness of spinal fusion in animal models. HSS J 2006; 2: 12-8.
25. Motomiya M, Ito M, Takahata M, et al. Effect of hydroxyapatite porous characteristics on healing outcomes in rabbit posterolateral spinal fusion model. Eur Spine J 2007; 16: 2215-24.
26. Cao Y, Mori S, Mashiba T, et al. Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats. J Bone Miner Res 2002; 17: 2237-46.
27. Ohta T, Komatsu S, Tokutake N, et al. Pharmacological and clinical properties of alendronate sodium hydrate [in Japanese]. Nippon Yakurigaku Zasshi 2002; 120 ( 6 ): 409-19.
28. Lin JH, Russell G, Gertz B. Pharmacokinetics of alendronate: an overview. Int J Clin Pract Suppl 1999; 101: 18-26.